Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
for monthly and quarterly dosing; Founder Daniel Santi, M.D., Ph.D., transitions to Chief Technical and Scientific Officer role EMERYVILLE, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced the closing of a $70 million Series A financing and the appointment of industry veteran Chris Boulton as Chief Executive Officer. The financing was co-led by 5AM Ventures and OrbiMed, along with Monograph Capital. The capital will be used to advance Prolynx's proprietary pipeline of extended-duration incretin and non-incretin therapies designed to enable monthly and quarterly dosing towards IND enablement and clinical proof-of-concept. The Company's approach to half-life extension utilizes a proprietary technology that has previously demonstrated clinical proof-of-concept in oncology, providing a de-risked foundation for the development of
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Doctor's Best Appoints Nate Challen as President [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesGlobeNewswire
- Why Wall Street Analysts Are Closely Watching Sanofi (SNY) [Yahoo! Finance]Yahoo! Finance
- InduPro Therapeutics Announces Strategic Investment from Sanofi and a Research Collaboration to Advance a Novel Bispecific for Autoimmune Disorders [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 12/12/25 - Form 6-K
- 12/3/25 - Form 6-K
- 11/18/25 - Form 6-K
- SNY's page on the SEC website